These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25186104)

  • 1. Immunohistochemical evidence for the association between attenuated mTOR signaling and diffuse alveolar damage, a fatal lung complication.
    Saito R; Yanai M; Miki Y; Fukasawa Y; Tominaga J; Ebina M; Sasano H
    Tohoku J Exp Med; 2014 Sep; 234(1):67-75. PubMed ID: 25186104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma.
    Jebali M; Elaidi R; Brizard M; Fouque J; Takouchop C; Sabatier B; Oudard S; Medioni J
    BMC Cancer; 2017 Jan; 17(1):27. PubMed ID: 28061764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with everolimus is associated with a procoagulant state.
    Baas MC; Gerdes VE; Ten Berge IJ; Heutinck KM; Florquin S; Meijers JC; Bemelman FJ
    Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
    Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
    Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation.
    Nava F; Cappelli G; Mori G; Granito M; Magnoni G; Botta C; Solazzo A; Fontana F; Baisi A; Bonucchi D
    Transplant Proc; 2014 Sep; 46(7):2263-8. PubMed ID: 25242766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analyses of alveolar epithelial injury via lipid-related stress in mammalian target of rapamycin inhibitor-induced lung disease.
    Kokuho N; Terasaki Y; Kunugi S; Saito Y; Urushiyama H; Terasaki M; Hayashi H; Gemma A; Shimizu A
    Lab Invest; 2019 Jun; 99(6):853-865. PubMed ID: 30728465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse events associated with mTOR inhibitors.
    Pallet N; Legendre C
    Expert Opin Drug Saf; 2013 Mar; 12(2):177-86. PubMed ID: 23252795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
    Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M
    Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
    Danesi R; Boni JP; Ravaud A
    Cancer Treat Rev; 2013 Nov; 39(7):784-92. PubMed ID: 23375248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience.
    Errasti P; Izquierdo D; Martín P; Errasti M; Slon F; Romero A; Lavilla FJ
    Transplant Proc; 2010 Oct; 42(8):3053-4. PubMed ID: 20970608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies.
    Ciccarese C; Iacovelli R; Brunelli M; Massari F; Bimbatti D; Fantinel E; De Marco V; Porcaro AB; Martignoni G; Artibani W; Tortora G
    Eur J Cancer; 2017 Sep; 83():237-246. PubMed ID: 28756136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus for the treatment of advanced renal cell carcinoma.
    Amato R
    Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
    Jonasch E; Signorovitch JE; Lin PL; Liu Z; Culver K; Pal SK; Scott JA; Vogelzang NJ
    Curr Med Res Opin; 2014 Oct; 30(10):2041-50. PubMed ID: 24983741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mammalian target of rapamycin: biological function and target for novel anticancer agents.
    Borders EB; Bivona C; Medina PJ
    Am J Health Syst Pharm; 2010 Dec; 67(24):2095-106. PubMed ID: 21116000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
    Wysocki PJ
    Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm.
    Willemsen AE; Grutters JC; Gerritsen WR; van Erp NP; van Herpen CM; Tol J
    Int J Cancer; 2016 May; 138(10):2312-21. PubMed ID: 26452336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Tyrosine Kinase Inhibitor
    Miyake H; Imai S; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
    Anticancer Res; 2017 Mar; 37(3):1523-1528. PubMed ID: 28314328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity.
    Hoerning A; Wilde B; Wang J; Tebbe B; Jing L; Wang X; Jian F; Zhu J; Dolff S; Kribben A; Hoyer PF; Witzke O
    Transplantation; 2015 Jan; 99(1):210-9. PubMed ID: 25099702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological targeting of mammalian target of rapamycin inhibits ovarian granulosa cell tumor growth.
    Rico C; Laguë MN; Lefèvre P; Tsoi M; Dodelet-Devillers A; Kumar V; Lapointe E; Paquet M; Nadeau MÈ; Boerboom D
    Carcinogenesis; 2012 Nov; 33(11):2283-92. PubMed ID: 22871496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations of hypoxia-induced factor signaling pathway due to mammalian target of rapamycin (mTOR) suppression in ovarian clear cell adenocarcinoma: in vivo and in vitro explorations for clinical trial.
    Hirasawa T; Miyazawa M; Yasuda M; Shida M; Ikeda M; Kajiwara H; Matsui N; Fujita M; Muramatsu T; Mikami M
    Int J Gynecol Cancer; 2013 Sep; 23(7):1210-8. PubMed ID: 23899586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.